ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act By Ogkologos - June 11, 2025 661 0 Facebook Twitter Google+ Pinterest WhatsApp Ensuring equitable access to cancer treatments remains central to EU health security efforts Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR ViPOR Regimen Associated with Durable Remissions in Patients with Specific Molecular... August 7, 2024 FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative... February 27, 2025 Detecting multiple cancers with a ‘simple’ blood test: Where are we? April 14, 2022 Sacituzumab Govitecan Demonstrates Overall Survival Benefit Over Chemotherapy in Patients with... September 18, 2023 Load more HOT NEWS Cancer clinical trials – learning lessons from the COVID-19 pandemic Impressive Responses to PD-1 Blockade in a Large Cohort of Children... EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical... On Giving Tuesday, You Helped Us Raise $334,449 For People, Pets,...
